STO-609 - CAS 52029-86-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
STO-609, a naphthoyl fused benzimidazole cell-permeable compound, is a potent and ATP-competitive inhibitor of the Ca2+/Calmodulin-dependent protein kinase kinase (CaM-KK) (CaM-KKα: Ki = 0.21 µM; CaM-KKβ: Ki = 40 nM). It inhibits CaMKK α and CaMKK β activities, and also suppresses AMP-activated protein kinase phosphorylation via binding to the CaMKK catalytic domain.
Brife Description:
A potent and ATP-competitive inhibitor of CaM-KK
99.90 %
Yellow solid Powder
STO-609; STO 609; STO609; 7-Oxo-7h-Benzimidazo[2,1-A]benz[de]isoquinoline-3-Carboxylic Acid; NCGC00025213-01
DMSO Solubility: 8 mg/mL (25.45 mM)
Store in a cool and dry place (or refer to the Certificate of Analysis).
Canonical SMILES:
1.Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.
Turner N;Li JY;Gosby A;To SW;Cheng Z;Miyoshi H;Taketo MM;Cooney GJ;Kraegen EW;James DE;Hu LH;Li J;Ye JM Diabetes. 2008 May;57(5):1414-8. doi: 10.2337/db07-1552. Epub 2008 Feb 19.
OBJECTIVE: ;Berberine (BBR) activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity in rodent models of insulin resistance. We investigated the mechanism of activation of AMPK by BBR and explored whether derivatization of BBR could improve its in vivo efficacy.;RESEARCH DESIGN AND METHODS: ;AMPK phosphorylation was examined in L6 myotubes and LKB1(-/-) cells, with or without the Ca(2+)/calmodulin-dependent protein kinase kinase (CAMKK) inhibitor STO-609. Oxygen consumption was measured in L6 myotubes and isolated muscle mitochondria. The effect of a BBR derivative, dihydroberberine (dhBBR), on adiposity and glucose metabolism was examined in rodents fed a high-fat diet. RESULTS; We have made the following novel observations: 1) BBR dose-dependently inhibited respiration in L6 myotubes and muscle mitochondria, through a specific effect on respiratory complex I, similar to that observed with metformin and rosiglitazone; 2) activation of AMPK by BBR did not rely on the activity of either LKB1 or CAMKKbeta, consistent with major regulation at the level of the AMPK phosphatase; and 3) a novel BBR derivative, dhBBR, was identified that displayed improved in vivo efficacy in terms of counteracting increased adiposity, tissue triglyceride accumulation, and insulin resistance in high-fat-fed rodents.
2.The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases.
Hurley RL;Anderson KA;Franzone JM;Kemp BE;Means AR;Witters LA J Biol Chem. 2005 Aug 12;280(32):29060-6. Epub 2005 Jun 24.
The AMP-activated protein kinase (AMPK) is an important regulator of cellular metabolism in response to metabolic stress and to other regulatory signals. AMPK activity is absolutely dependent upon phosphorylation of AMPKalphaThr-172 in its activation loop by one or more AMPK kinases (AMPKKs). The tumor suppressor kinase, LKB1, is a major AMPKK present in a variety of tissues and cells, but several lines of evidence point to the existence of other AMPKKs. We have employed three cell lines deficient in LKB1 to study AMPK regulation and phosphorylation, HeLa, A549, and murine embryo fibroblasts derived from LKB(-/-) mice. In HeLa and A549 cells, mannitol, 2-deoxyglucose, and ionomycin, but not 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR), treatment activates AMPK by alphaThr-172 phosphorylation. These responses, as well as the downstream effects of AMPK on the phosphorylation of acetyl-CoA carboxylase, are largely inhibited by the Ca(2+)/ calmodulin-dependent protein kinase kinase (CaMKK) inhibitor, STO-609. AMPKK activity in HeLa cell lysates measured in vitro is totally inhibited by STO-609 with an IC50 comparable with that of the known CaMKK isoforms, CaMKKalpha and CaMKKbeta.
3.Activation of the prolyl-hydroxylase oxygen-sensing signal cascade leads to AMPK activation in cardiomyocytes.
Yan H;Zhang DX;Shi X;Zhang Q;Huang YS J Cell Mol Med. 2012 Sep;16(9):2049-59. doi: 10.1111/j.1582-4934.2011.01500.x.
The proline hydroxylase domain-containing enzymes (PHD) act as cellular oxygen sensors and initiate a hypoxic signal cascade to induce a range of cellular responses to hypoxia especially in the aspect of energy and metabolic homeostasis regulation. AMP-activated protein kinase (AMPK) is recognized as a major energetic sensor and regulator of cardiac metabolism. However, the effect of PHD signal on AMPK has never been studied before. A PHD inhibitor (PHI), dimethyloxalylglycine and PHD2-specific RNA interference (RNAi) have been used to activate PHD signalling in neonatal rat cardiomyocytes. Both PHI and PHD2-RNAi activated AMPK pathway in cardiomyocytes effectively. In addition, the increased glucose uptake during normoxia and enhanced myocyte viability during hypoxia induced by PHI pretreatment were abrogated substantially upon AMPK inhibition with an adenoviral vector expressing a dominant negative mutant of AMPK-α1. Furthermore, chelation of intracellular Ca2+ by BAPTA, inhibition of calmodulin-dependent kinase kinase (CaMKK) with STO-609, or RNAi-mediated down-regulation of CaMKK α inhibited PHI-induced AMPK activation significantly. In contrast, down-regulation of LKB1 with adenoviruses expressing the dominant negative form did not affect PHI-induced AMPK activation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CaMK-II Products

CAS 167114-91-2 Autocamtide-2-related inhibitory peptide

Autocamtide-2-related inhibitory peptide
(CAS: 167114-91-2)

Autocamtide-2-related inhibitory peptide is a highly selective, specific and potent inhibitor of calmodulin-dependent protein kinase II (CaM kinase II) with I50...

CAS 201422-04-0 Autocamtide-2-related inhibitory peptide, myristoylated

Autocamtide-2-related inhibitory peptide
(CAS: 201422-04-0)

Autocamtide-2-related inhibitory peptide, myristoylated is a CaM kinase II inhibitor. It is an enhanced cell-permeable derivative of autocamtide-2-related inhib...

CAS 176708-42-2 KN-92

(CAS: 176708-42-2)

KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 inhibits histamine-induced aminopy...

CAS 139298-40-1 KN-93

(CAS: 139298-40-1)

KN-93 is a selective Ca2+/calmodulin-dependent protein kinase II inhibitor, which has been implicated in the regulation of smooth muscle contractility. CaM kina...

CAS 1135280-28-2 KN-92 phosphate

KN-92 phosphate
(CAS: 1135280-28-2)

KN-92 is an inactive analog of the CaM kinase II inhibitor KN 93.

CAS 108334-68-5 Syntide 2

Syntide 2
(CAS: 108334-68-5)

Syntide 2, a synthetic peptide, is recognized as a substrate by Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Ki= 12 μM) and protein kinase C (Km = 11 µ...

CAS 1208123-85-6 CaMKII-IN-1

(CAS: 1208123-85-6)

CaMKII-IN-1 is a potent and highly selective CaMKII inhibitor with IC50 of 63 nM; significantly high selectivity against CaMKIV, MLCK, p38a, Akt1, and PKC.

CAS 118458-54-1 Arcyriaflavin A

Arcyriaflavin A
(CAS: 118458-54-1)

Arcyriaflavin A is a potent dual target agent of calcium/calmodulin-dependent protein kinase II (CaMKII) and cyclin-dependent kinase 4 (CDK4). Its IC50 values a...

Chemical Structure

CAS 52029-86-4 STO-609

Quick Inquiry

Verification code

Featured Items